Literature DB >> 18604160

IRF6 in development and disease: a mediator of quiescence and differentiation.

Caleb M Bailey1, Mary J C Hendrix.   

Abstract

Post utero development of the mammary gland is a complex developmental process characterized by states of rapid cell proliferation (branching morphogenesis) followed by functional differentiation (lactation) and the consequent apoptosis (involution) of the secretory mammary epithelial cell. This process is cyclical, such that involution returns the mammary gland to a near-virgin-like state capable of responding to morphogenic cues with each consecutive pregnancy. Importantly, many of the regulatory processes which oversee mammary gland development are corrupted or otherwise compromised during the development of breast cancer. For example, Interferon Regulatory Factor 6 (IRF6) is a novel protein with growth inhibitory properties that was initially identified in mammary epithelial cells through its interaction with maspin, a known tumor suppressor in normal breast tissue. Recent findings from our laboratory suggest that IRF6 functions synergistically with maspin to regulate mammary epithelial cell differentiation by acting on the cell cycle. This perspective focuses on the possible involvement of IRF6 in promoting differentiation by regulating exit from the cell cycle and entry into the G(0) phase of cellular quiescence, and how these new findings shed light on normal mammary gland development and the initiation and progression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18604160      PMCID: PMC2581479          DOI: 10.4161/cc.7.13.6221

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  52 in total

Review 1.  IRF family of transcription factors as regulators of host defense.

Authors:  T Taniguchi; K Ogasawara; A Takaoka; N Tanaka
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Inhibition of CDK2, CDK4 and cyclin E and increased expression of p27Kip1 during treatment with interferon-alpha in carcinoid tumor cells.

Authors:  Y Zhou; S Wang; A Gobl; K Oberg
Journal:  J Biol Regul Homeost Agents       Date:  1999 Oct-Dec       Impact factor: 1.711

3.  In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation.

Authors:  Tim G A M Wolfs; Wim A Buurman; Annemarie van Schadewijk; Bart de Vries; Marc A R C Daemen; Pieter S Hiemstra; Cornelis van 't Veer
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

4.  Maspin sensitizes breast carcinoma cells to induced apoptosis.

Authors:  Ning Jiang; Yonghong Meng; Suliang Zhang; Edith Mensah-Osman; Shijie Sheng
Journal:  Oncogene       Date:  2002-06-13       Impact factor: 9.867

5.  Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability.

Authors:  K Nakagawa; H Yokosawa
Journal:  Eur J Biochem       Date:  2000-03

6.  CD14-dependent lipopolysaccharide-induced beta-defensin-2 expression in human tracheobronchial epithelium.

Authors:  M N Becker; G Diamond; M W Verghese; S H Randell
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

7.  Oncogenic potential of a dominant negative mutant of interferon regulatory factor 3.

Authors:  Tae Young Kim; Kyoung-Hu Lee; Seungwoo Chang; Cheolho Chung; Han-Woong Lee; Jeongbin Yim; Tae Kook Kim
Journal:  J Biol Chem       Date:  2003-02-10       Impact factor: 5.157

8.  Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers.

Authors:  H Suzuki; F Itoh; M Toyota; T Kikuchi; H Kakiuchi; K Imai
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

9.  Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells.

Authors:  Valerie A Odero-Marah; Zhila Khalkhali-Ellis; Jirapat Chunthapong; Sumaira Amir; Richard E B Seftor; Elisabeth A Seftor; Mary J C Hendrix
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

10.  Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes.

Authors:  Shinji Kondo; Brian C Schutte; Rebecca J Richardson; Bryan C Bjork; Alexandra S Knight; Yoriko Watanabe; Emma Howard; Renata L L Ferreira de Lima; Sandra Daack-Hirsch; Achim Sander; Donna M McDonald-McGinn; Elaine H Zackai; Edward J Lammer; Arthur S Aylsworth; Holly H Ardinger; Andrew C Lidral; Barbara R Pober; Lina Moreno; Mauricio Arcos-Burgos; Consuelo Valencia; Claude Houdayer; Michel Bahuau; Danilo Moretti-Ferreira; Antonio Richieri-Costa; Michael J Dixon; Jeffrey C Murray
Journal:  Nat Genet       Date:  2002-09-03       Impact factor: 38.330

View more
  17 in total

Review 1.  The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin.

Authors:  Margarida M Bernardo; Sijana H Dzinic; Maria J Matta; Ivory Dean; Lina Saker; Shijie Sheng
Journal:  J Cell Biochem       Date:  2017-03-21       Impact factor: 4.429

2.  Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.

Authors:  Thomas Fleischer; Arnoldo Frigessi; Kevin C Johnson; Hege Edvardsen; Nizar Touleimat; Jovana Klajic; Margit Lh Riis; Vilde D Haakensen; Fredrik Wärnberg; Bjørn Naume; Aslaug Helland; Anne-Lise Børresen-Dale; Jörg Tost; Brock C Christensen; Vessela N Kristensen
Journal:  Genome Biol       Date:  2014-08-22       Impact factor: 13.583

3.  Generation and characterization of a conditional allele of Interferon Regulatory Factor 6.

Authors:  Arianna L Smith; Youssef A Kousa; Akira Kinoshita; Kate Fodor; Baoli Yang; Brian C Schutte
Journal:  Genesis       Date:  2017-06-22       Impact factor: 2.487

4.  p63 and IRF6: brothers in arms against cleft palate.

Authors:  Amel Gritli-Linde
Journal:  J Clin Invest       Date:  2010-04-26       Impact factor: 14.808

5.  Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs).

Authors:  Adriana S Beltran; Pilar Blancafort
Journal:  Epigenetics       Date:  2011-02-01       Impact factor: 4.528

6.  TLR3 drives IRF6-dependent IL-23p19 expression and p19/EBI3 heterodimer formation in keratinocytes.

Authors:  Divya Ramnath; Kathryn Tunny; Daniel M Hohenhaus; Claire M Pitts; Anne-Sophie Bergot; P Mark Hogarth; John A Hamilton; Ronan Kapetanovic; Richard A Sturm; Glen M Scholz; Matthew J Sweet
Journal:  Immunol Cell Biol       Date:  2015-08-25       Impact factor: 5.126

7.  Using neural networks for reducing the dimensions of single-cell RNA-Seq data.

Authors:  Chieh Lin; Siddhartha Jain; Hannah Kim; Ziv Bar-Joseph
Journal:  Nucleic Acids Res       Date:  2017-09-29       Impact factor: 16.971

8.  Interferon regulatory factor 6 (IRF6) is expressed in the ovine uterus and functions as a transcriptional activator.

Authors:  Jo-Ann G W Fleming; Gwonhwa Song; Youngsok Choi; Thomas E Spencer; Fuller W Bazer
Journal:  Mol Cell Endocrinol       Date:  2008-10-30       Impact factor: 4.102

9.  IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes.

Authors:  Gaetana Restivo; Bach-Cuc Nguyen; Piotr Dziunycz; Elodie Ristorcelli; Russell J H Ryan; Özden Yalçin Özuysal; Matteo Di Piazza; Freddy Radtke; Michael J Dixon; Günther F L Hofbauer; Karine Lefort; G Paolo Dotto
Journal:  EMBO J       Date:  2011-11-16       Impact factor: 11.598

10.  The IRF family of transcription factors: Inception, impact and implications in oncogenesis.

Authors:  Hideyuki Yanai; Hideo Negishi; Tadatsugu Taniguchi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.